24.10.2014 • News

Vetter Announces Personnel Changes in its Development Service Division

Dr. Susanne Resatz has been appointed as President of Vetters clinical...
Dr. Susanne Resatz has been appointed as President of Vetter's clinical development facility in Chicago, Illinois.

Dr. Susanne Resatz, formerly Manager Process Development and Manufacturing at Vetter's clinical development facility in Chicago, Illinois, has assumed the role of President. Resatz will be fully responsible for the site's operations. Dr. Claudia Roth, who held this position before, will repatriate to the company headquarters in Ravensburg, Germany where she will head up the newly created "Innovation" department. Both Resatz and Roth have been with Vetter's US facility since its opening in 2009, and were instrumental in its early construction through to its becoming fully operational in October 2011. Resatz's expertise includes designing and implementing highly efficient, high-quality manufacturing processes for early-stage products. She holds a PhD in biomedical engineering from the Vienna University of Technology.

Vetter also announced that Dr. Paul Nelles, who headed Vetter´s global Development Service activities, will take early retirement after 11 years of service with Vetter. His replacement, Dr. Claus Feussner, formerly vice president Quality Control, has assumed the title of senior vice President of Vetter Development Service effective September 1. Nelles will continue with his efforts at Vetter until mid-2015 to help with the transition.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read